E. Garry Menzel - Dec 7, 2022 Form 4 Insider Report for TCR2 THERAPEUTICS INC. (TCRR)

Role
President and CEO, Director
Signature
/s/ Margaret Siegel as Attorney-in-Fact
Stock symbol
TCRR
Transactions as of
Dec 7, 2022
Transactions value $
-$23,360
Form type
4
Date filed
12/9/2022, 03:44 PM
Previous filing
Dec 7, 2022
Next filing
Dec 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TCRR Common Stock Sale -$11.7K -9.11K -4.81% $1.28 180K Dec 7, 2022 Direct F3
transaction TCRR Common Stock Sale -$11.7K -9.31K -5.17% $1.25 171K Dec 8, 2022 Direct F3
holding TCRR Common Stock 133K Dec 7, 2022 See Footnote F1
holding TCRR Common Stock 133K Dec 7, 2022 See Footnote F2
holding TCRR Common Stock 189K Dec 7, 2022 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of 132,729 shares of common stock held by the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Menzel Trust"). The reporting person is the trustee of the Menzel Trust, and as such the reporting person may be deemed to beneficially own such securities. The reporting person and members of his immediate family are the sole beneficiaries of the Menzel Trust.
F2 Consists of 132,730 shares of common stock held by and the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Henshall Trust"). The reporting person's spouse is the trustee of the Henshall Trust, and as such the reporting person may be deemed to beneficially own such securities. The reporting person and members of his immediate family are the sole beneficiaries of the Henshall Trust.
F3 The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.